The impact of concurrent autoimmune thyroid disease on the tumour microenvironment and disease progression in papillary thyroid cancer (PTC) is not well understood. Studies evaluating the programmed cell death ligand 1 (PD-L1) tumour expression in PTC have shown variable results, and the effect of lymphocytic thyroiditis (LT) on tumour PD-L1 expression has not been adequately assessed. The main aim of this study was to determine expression of PD-L1 in PTC with and without LT. We examined 81 PTC cases; 28.5% of all reviewed PTC had presence of LT. In PTC specimens without LT, tumour PD-L1 expression was significantly lower compared to PD-L1 expression in PTC with LT, 6.9% vs 39.1%, respectively. Expression of PD-L1 did not differ with PTC stage, even when sub-categorised according to the presence and absence of LT. Utility of PD- L1 expression as a prognostic marker in thyroid cancer needs to be interpreted with caution.

Item Type:	Refereed Article
Keywords:	PD-L, Papillary thyroid cancer, lymphocytic thyroiditis, programmed cell death ligand 1, tumour microenvironment
Research Division:	Biomedical and Clinical Sciences
Research Group:	Clinical sciences
Research Field:	Pain
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Treatment of human diseases and conditions
UTAS Author:	Greenaway, TM (Dr Tim Greenaway)
ID Code:	152366
Year Published:	2020
Web of Science® Times Cited:	7
Deposited By:	Medicine
Deposited On:	2022-08-18
Last Modified:	2022-11-25
Downloads:	0